AstraZeneca has announced the acquisition of EsoBiotec, a company pioneering innovative approaches in the realm of immune cell engineering. The acquisition, valued at $425 million upfront with additional potential milestone payments of up to $575 million, signals AstraZeneca’s commitment to advancing the next generation of therapies designed to combat cancer and autoimmune diseases. EsoBiotec, based…